CD33 and acute myeloid leukemia: Subsequently, a Phase II trial in 142 older patients with first relapse of AML used GO at 9 mg/m2 (dose that stably saturates 75% of CD33) with an overall response rate (ORR) of 30% consisting of a complete remission (CR) rate of 16% and a CRp (without platelets recovery) of 13% [31].